Male Hypogonadism - Pipeline Review, H2 2018

  • ID: 4592412
  • Report
  • 101 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Antares Pharma Inc
  • Diurnal Group Plc
  • Lipocine Inc
  • Medlab Clinical Ltd
  • Mereo Biopharma Group Plc
  • TesoRx Pharma LLC
  • MORE
Male Hypogonadism - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Pipeline Review, H2 2018, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights:

This latest pipeline guide Male Hypogonadism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 4, 5, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Antares Pharma Inc
  • Diurnal Group Plc
  • Lipocine Inc
  • Medlab Clinical Ltd
  • Mereo Biopharma Group Plc
  • TesoRx Pharma LLC
  • MORE
Introduction

Report Coverage

Male Hypogonadism - Overview

Male Hypogonadism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Male Hypogonadism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Male Hypogonadism - Companies Involved in Therapeutics Development

Antares Pharma Inc

Clarus Therapeutics Inc

Diurnal Group Plc

EndoCeutics Inc

Ferring International Center SA

Lipocine Inc

M et P Pharma AG

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

Repros Therapeutics Inc

TesoRx Pharma LLC

Viramal Ltd

Male Hypogonadism - Drug Profiles

chorionic gonadotropin ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corifollitropin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enclomiphene citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IAS-167A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kisspeptin-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leflutrozole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leuprolide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Libidua - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone enanthate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VERU-722 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Male Hypogonadism - Dormant Projects

Male Hypogonadism - Discontinued Products

Male Hypogonadism - Product Development Milestones

Featured News & Press Releases

Jun 14, 2018: Acerus Announces Approval of NATESTO in South Korea

May 03, 2018: Aytu BioScience Provides Update on Natesto

Apr 05, 2018: Acerus to Present at the Next CHINABIO Partnering Forum

Apr 05, 2018: Antares Pharma Provides Update on XYOSTED

Mar 27, 2018: Antares Pharma Announces XYOSTED Regulatory Update

Mar 20, 2018: Aytu BioScience Presents New Research Findings for Natesto at the Endocrine Society’s 100th Annual Meeting

Mar 19, 2018: Mereo BioPharma Announces Positive Top-Line Results from Phase 2b Study of BGS-649 for the Treatment of Hypogonadotropic Hypogonadism in Obese Men

Mar 15, 2018: Ferring announces positive outcome of European Decentralised Procedure for Testavan, a treatment for men with hypogonadism

Feb 02, 2018: Acerus Pharma’s NATESTO to Be Listed for Public Reimbursement in Quebec, Building on Strong 28% Increase in Natesto’s Canadian Prescriptions in Q4 2

Jan 26, 2018: Repros Announces Negative Opinion From the EMA for Enclomiphene

Jan 16, 2018: Antares Pharma Provides XYOSTED Regulatory Update 2018

Dec 21, 2017: Antares Pharma Provides Regulatory Update on XYOSTED

Dec 15, 2017: Repros Therapeutics Receives Feedback Following an Oral Explanation with the European Medicines Agency

Dec 06, 2017: Acerus Enters into Loan Facility to Support Anticipated Product Launch and Sales and Marketing Initiatives

Nov 30, 2017: Acerus Secures CDN$1.6M of New NATESTO Orders from Its U.S. Licensee Aytu Bioscience

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Male Hypogonadism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Male Hypogonadism - Pipeline by Antares Pharma Inc, H2 2018

Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H2 2018

Male Hypogonadism - Pipeline by Diurnal Group Plc, H2 2018

Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2018

Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2018

Male Hypogonadism - Pipeline by Lipocine Inc, H2 2018

Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2018

Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2018

Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2018

Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2018

Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2018

Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2018

Male Hypogonadism - Pipeline by Viramal Ltd, H2 2018

Male Hypogonadism - Dormant Projects, H2 2018

Male Hypogonadism - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Male Hypogonadism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Antares Pharma Inc
  • Clarus Therapeutics Inc
  • Diurnal Group Plc
  • EndoCeutics Inc
  • Ferring International Center SA
  • Lipocine Inc
  • M et P Pharma AG
  • Medlab Clinical Ltd
  • Merck & Co Inc
  • Mereo Biopharma Group Plc
  • Repros Therapeutics Inc
  • TesoRx Pharma LLC
  • Viramal Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll